Progress of sequential immunization with vaccines against SARS-CoV-2
10.3760/cma.j.cn112866-20220331-00076
- VernacularTitle:SARS-CoV-2疫苗序贯免疫的研究进展
- Author:
Xinghang LI
1
;
Qihan LI
Author Information
1. 中国医学科学院北京协和医学院医学生物学研究所 云南省重大传染病疫苗研发重点实验室，昆明 650118
- Keywords:
Severe acute respiratory syndrome coronavirus 2;
Coronavirus disease 2019;
Sequential immunization;
Vaccine
- From:
Chinese Journal of Experimental and Clinical Virology
2022;36(3):327-336
- CountryChina
- Language:Chinese
-
Abstract:
Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2 infection is one of the most threatening infectious diseases facing humanity in this century. Currently, four classes of vaccines have been approved for marketing or authorized for emergency use worldwide, including inactivated vaccines, mRNA vaccines, adenovirus-based vector vaccines, and recombinant protein vaccines. As the COVID-19 pandemic continues and antibody levels in the fully immunized population gradually decrease, booster immunization is a necessary measure, and sequential immunization strategies appear to be a better vaccination strategy. In this paper, the research on four different technical routes of vaccines in sequential immunization is reviewed.
